Toujeo from Sanofi S.A. - concentrated insulin aiming to simplify type 2 diabetes dosing

Toujeo delivers 300 units/mL of insulin glargine in a compact prefilled pen for adults living with type 2 diabetes in the US. Anyone holding Sanofi S.A. stock (NASDAQ: SNY, ISIN FR0000120578) should know this product.

By Daniel Foster, ad hoc news New Launch Desk. Reviewed June 30, 2026, 11:55 AM ET. Details in the imprint.

Toujeo 300 units/mL insulin glargine injection sits cold in the fridge door, a squat prefilled pen in a pale green box that many US adults with type 2 diabetes now reach for every morning. One twist on the dial, a quick click under the skin, and the day’s basal insulin is done.

What Toujeo is offering

Toujeo is Sanofi S.A.’s concentrated long-acting insulin glargine formulation, delivering 300 units/mL in SoloStar and Max SoloStar prefilled pens for once-daily subcutaneous injection in adults with type 1 and type 2 diabetes. Official Toujeo US product information According to Sanofi, the higher concentration allows the same dose of insulin in a smaller injection volume compared with standard 100 units/mL glargine. FDA-approved prescribing information

In practice, that smaller volume can mean less injection-site discomfort for some patients and more compact pens that are easier to carry to work or while traveling. In clinical studies submitted to the US Food and Drug Administration, Toujeo showed comparable HbA1c reductions to earlier glargine formulations, with a different profile of hypoglycemia risk that clinicians consider when choosing long-acting insulin therapy. Clinical comparison of 300 vs 100 units/mL glargine

US access, pricing and real-world use

For US patients, Toujeo is widely available through retail and mail-order pharmacies, typically as 1.5 mL or 3 mL disposable pens, with national wholesalers listing it under the insulin glargine 300 units/mL category. Toujeo pricing snapshots Recent US price comparison data show cash prices in the several-hundred-dollar range per box of pens before insurance or manufacturer savings programs, putting it firmly in the branded insulin tier for out-of-pocket costs.

Endocrinologists such as Dr. Anne Peters at the University of Southern California have discussed concentrated basal insulins like Toujeo as tools to fine-tune glycemic control, particularly in people needing higher daily doses where injection volume starts to matter. Expert discussion on concentrated basal insulins In clinic rooms, that translates to conversations about timing and dose adjustments rather than swapping pens every few days just to keep up with units.

How Toujeo fits into Sanofi’s diabetes portfolio

Sanofi positions Toujeo as a next-generation basal insulin option in a global diabetes business that also features insulins like Lantus and newer combinations and injectables. Sanofi diabetes portfolio overview While Sanofi does not break out Toujeo sales in every quarterly disclosure, diabetes and cardiovascular products remain a core revenue pillar in its Specialty Care and General Medicines segments.

In Sanofi’s recent earnings presentations, Chief Executive Officer Paul Hudson has repeatedly highlighted diabetes as an area where the company is optimizing its mix of mature brands and newer treatments to keep margins resilient amid pricing pressure in key markets. Sanofi investor presentations Toujeo, as a branded basal insulin with broad reimbursement in the US, is one of the products that helps Sanofi maintain a presence against rivals like Novo Nordisk and Eli Lilly in the basal segment.

Product details and clinical profile

Toujeo’s 300 units/mL concentration yields a flatter and more prolonged glucose-lowering profile than 100 units/mL insulin glargine in pharmacodynamic studies, which can translate into potentially lower risk of nocturnal hypoglycemia for some patients when dosed appropriately. Clinical review of Toujeo’s profile The FDA-approved labeling underscores that individual hypoglycemia risk still depends on diet, activity and other medications, so prescribers adjust doses carefully.

The SoloStar and Max SoloStar devices give patients the ability to dial doses in one-unit increments, with Max SoloStar designed for higher daily doses up to 160 units per injection in adults who need larger basal amounts. Pen device features In the hand, the pen feels similar to other modern insulin pens: matte plastic barrel, a clear window showing remaining solution, and a tactile dose knob that clicks audibly as you turn.

In pivotal trials such as EDITION studies, Toujeo achieved noninferior HbA1c reductions compared with 100 units/mL glargine, with some analyses suggesting fewer hypoglycemic events in certain time windows, particularly at night. EDITION trial data For US prescribers, that evidence feeds into individualized choices: some patients stay on older formulations, others are moved to Toujeo when dose and risk balance make sense.

US payer landscape and patient support

Like other branded insulins, Toujeo’s real-world uptake depends heavily on US payer decisions. Commercial plans, Medicare Part D formularies and Medicaid programs put Toujeo through tiered coverage and prior authorization rules, sometimes preferring specific basal insulins based on negotiated rebates. Formulary status overview For physicians, that means more time spent checking whether Toujeo is covered before writing the prescription.

Sanofi runs US patient support programs that can lower out-of-pocket costs for eligible commercially insured patients via copay cards and other offers, although these do not apply to government-insured beneficiaries. Toujeo patient support From the patient’s perspective, the difference between paying a few tens of dollars per month and several hundred dollars can decide whether they can stick with Toujeo or need to switch to lower-cost alternatives.

Regulatory status and safety considerations

Toujeo received its initial FDA approval for adults with diabetes in 2015, based on a dossier that included pharmacology, manufacturing and clinical trial data, and its label has been updated over time to reflect postmarketing experience. FDA NDA archive As with all insulins, the prescribing information carries warnings about hypoglycemia, hypersensitivity reactions and possible changes in injection-site lipodystrophy.

Care teams typically walk new Toujeo users through safe injection technique, rotation of injection sites and how to respond to low blood sugar episodes. In coaching sessions, diabetes educators often ask patients to show back how they prime the pen, dial the dose and count the seconds after pressing the plunger, turning a printed label into practical routine.

Sanofi context and stock lens

Sanofi S.A. frames Toujeo as part of a broader effort to refine its endocrinology lineup while it also invests heavily in immunology, oncology and rare disease pipelines, including recent AI-supported discovery partnerships in inflammatory conditions. AI discovery collaboration coverage For US retail investors, Toujeo is one piece of a diversified product base that generates recurring revenue in a chronic disease area with ongoing demand.

Sanofi S.A. stock (NASDAQ: SNY, ISIN FR0000120578) trades in US dollars as an American depositary receipt, giving US investors exposure to this diabetes franchise alongside the company’s wider specialty-care portfolio.

Toujeo insulin glargine 300 units/mL at a glance

• Product: Toujeo 300 units/mL insulin glargine injection
• Manufacturer: Sanofi S.A.
• Category: New launch basal insulin (pharmaceutical)
• Launch: First FDA approval 2015, ongoing label and market updates
• MSRP / Price: Typically several hundred USD per box of pens before insurance; actual US pharmacy prices vary by plan and discount
• Availability: Prescription-only, widely available through US retail and mail-order pharmacies
• Target audience: Adults with type 2 diabetes and adults with type 1 diabetes requiring once-daily long-acting basal insulin, under physician supervision
• Standout / USP: Concentrated 300 units/mL formulation in compact pens, aiming for a flatter, longer-acting glucose-lowering profile and reduced injection volume compared with standard 100 units/mL glargine

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.